Business Context and Reporting Period
This Form 8-K was filed by GRI Bio, Inc. on September 10, 2024. The report addresses a notification received from the Listing Qualifications Department of The Nasdaq Stock Market, LLC regarding the Company's compliance with listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on stock listing compliance rather than financial performance metrics.
Material Changes
The material change reported is the Company's failure to meet the Nasdaq Listing Rule 5550(a)(2) Minimum Bid Price Requirement. The closing bid price for the Company's common stock was less than $1.00 for the previous 30 consecutive business days.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted a 180-calendar day period, until March 10, 2025, to regain compliance.
- Compliance Criteria: To regain compliance, the common stock must maintain a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the compliance period.
- Delisting Risk: If the closing bid price falls to $0.10 per share or less for ten consecutive trading days before the Compliance Date, Nasdaq may issue a Staff Delisting Determination.
- Management Action: The Company is monitoring the stock price and will consider options to regain compliance, though there is no assurance of success.
Investor Verification Checklist
- Verify the current closing bid price of GRI Bio, Inc. (GRI) to assess proximity to the $1.00 compliance threshold.
- Monitor for any reverse stock split announcements or other corporate actions intended to increase the share price.
- Track the stock price for any periods where it falls to $0.10 or less, which could trigger immediate delisting proceedings.
- Review future filings for updates on the Company's progress toward the March 10, 2025 Compliance Date.